logo
R&D Tax Credits

Achieving substantial uplift on previous claims for Ariane Medical Systems

“With such a substantial uplift on our previous claims we were obviously extremely happy with Ayming and its experts. They were able to understand the way we work and what our priorities were quickly and efficiently, leaving us to carry on with business as usual. I’d happily recommend them to other companies working within the medical industry.”

 

-  Keith Spanswick, Executive Chairman, Ariane Medical Systems

The Company

Ariane Medical Systems Ltd formed in 2005 to optimise the development of a low energy X-ray Brachytherapy system, used in the treatment of lower rectal tumours.

The company teamed up with clinical partners to develop this cutting edge, life-saving technology, which is now treating patients in the UK, as well as Denmark, France, Sweden and Switzerland.

Ariane medical systems was looking for much needed investment and needed to ensure its R&D claim was fully optimised.

The Project

Ariane developed The Papillon 50, the first of its kind and a revolutionary radiotherapy procedure for patients who have been diagnosed with early rectal cancer, but who aren’t fit enough for anaesthesia.

Key advances included:

  • Control of radiation output
  • Reduction of heat from x-ray generator
  • Ability to treat cancers smaller than 20mm
  • Integration of endoscopy into the machine
  • Ability to withstand intensive cleaning and disinfection protocols

And How We Helped...

The Ayming UK R&D tax team successfully compiled and submitted two uplift claims on behalf of Ariane Medical Systems, identifying a huge increase in qualifying expenditure over what had previously been identified:

2014:  £218,833 of qualifying expenditure, an uplift of 152.35%

2015:  £170,765 of qualifying expenditure, an uplift of 145.60%

Ariane Medical Systems Logo

About Ariane Medical Systems

Ariane Medical Systems is a medical device developer and manufacturer specialising in the use of low energy X-rays for the treatment of accessible tumours.